|
|
 |
|
Viewing report
|
|
|
|
Q4 2010 BioMedTracker Outlook Report
Sagient Research, Oct 2010, Pages: 23
The Q3 2010 report detailed several significant catalysts that resulted in doubledigit stock price changes, details of which can be found in the table on Page 2 of this report.
This Q4 2010 report covers a number of catalysts from 21 drugs, one device and one diagnostic, highlighted by news in the cardiovascular, metabolic and Hepatitis C spaces. Additionally, we have included comprehensive calendars for the remainder of 2010 from our sister product, CatalystTracker, of Large Impact catalysts in the drug, device/diagnostic and natural resource areas.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Global Biopharma Outlook 2012 - Major US and EU Pharma
Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition
Will Next Generation Oral Anticoagulants Replace Warfarin as Mainstay Therapy?
Global Biopharma Outlook 2011: Major US and EU
Global Biopharma Outlook 2011
Thought Leader Insight & Analysis Report - Cardiovascular Q4 2011
Cardiovascular Disease Diagnostics - Global Strategic Business Report
Global Atrial Fibrillation Market Report: 2011 Edition
Personalized Medicine - Scientific and Commercial Aspects
Global Hepatitis C Virus (HCV) Market– An Analysis
|
|
|
|
